{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:14:50Z","timestamp":1740107690705,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pfizer GmbH","award":["WI 186174"],"award-info":[{"award-number":["WI 186174"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s10067-020-05316-9","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T05:18:52Z","timestamp":1597987132000},"page":"887-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose tapering of biologic agents in patients with rheumatoid arthritis\u2014results from a cohort study in Germany"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0600-2803","authenticated-orcid":false,"given":"Dietmar","family":"Krause","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-7756","authenticated-orcid":false,"given":"Carolin","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Rudolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmar","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"5316_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"5316_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","volume":"77","author":"C Fiehn","year":"2018","unstructured":"Fiehn C, Holle J, Iking-Konert C et al (2018) S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs. Z Rheumatol 77:35\u201353","journal-title":"Z Rheumatol"},{"key":"5316_CR3","doi-asserted-by":"crossref","unstructured":"Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386:258\u2013265","DOI":"10.1016\/S0140-6736(14)61704-9"},{"key":"5316_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3\u201315","journal-title":"Ann Rheum Dis"},{"key":"5316_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","volume":"75","author":"J Haschka","year":"2016","unstructured":"Haschka J, Englbrecht M, Hueber AJ et al (2016) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 75:45\u201351","journal-title":"Ann Rheum Dis"},{"key":"5316_CR6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","volume":"381","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Nash P, Durez P et al (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381:918\u2013929","journal-title":"Lancet"},{"key":"5316_CR7","doi-asserted-by":"publisher","unstructured":"Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L (2018) Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/s13075-017-1484-9","DOI":"10.1186\/s13075-017-1484-9"},{"key":"5316_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/annrheumdis-2017-212423","volume":"77","author":"S Henaux","year":"2018","unstructured":"Henaux S, Ruyssen-Witrand A, Cantagrel A et al (2018) Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis 77:515\u2013522","journal-title":"Ann Rheum Dis"},{"key":"5316_CR9","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","volume":"75","author":"G Schett","year":"2016","unstructured":"Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, Fautrel B, van Vollenhoven R (2016) Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 75:1428\u20131437","journal-title":"Ann Rheum Dis"},{"key":"5316_CR10","doi-asserted-by":"publisher","unstructured":"Verhoef LM, van den Bemt BJ, van der Maas A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, Jacobs WC, van Herwaarden N, den Broeder AA (2019) Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 24;5:CD010455. https:\/\/doi.org\/10.1002\/14651858.CD010455.pub3","DOI":"10.1002\/14651858.CD010455.pub3"},{"issue":"S5","key":"5316_CR11","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1002\/art.11407","volume":"49","author":"J Fransen","year":"2003","unstructured":"Fransen J, Stucki G, van Riel PL (2003) Rheumatoid arthritis measures: disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI). Arthritis Care Res 49(S5):S214\u2013S224","journal-title":"Arthritis Care Res"},{"key":"5316_CR12","first-page":"64","volume":"34","author":"J Zochling","year":"2007","unstructured":"Zochling J, Stucki G, Grill E, Braun J (2007) A comparative study of patient-reported functional outcomes in acute rheumatoid arthritis. J Rheumatol 34:64\u201369","journal-title":"J Rheumatol"},{"key":"5316_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/acr.22456","volume":"67","author":"BR England","year":"2015","unstructured":"England BR, Sayles H, Mikuls TR et al (2015) Validation of the rheumatic disease comorbidity index. Arthritis Care Res 67:865\u2013872","journal-title":"Arthritis Care Res"},{"key":"5316_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","volume":"75","author":"RF van Vollenhoven","year":"2016","unstructured":"van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M et al (2016) Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 75:52\u201358","journal-title":"Ann Rheum Dis"},{"key":"5316_CR15","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1136\/annrheumdis-2011-200945","volume":"71","author":"A van der Maas","year":"2012","unstructured":"van der Maas A, Kievit W, van den Bemt BJ et al (2012) Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 71:1849\u20131854","journal-title":"Ann Rheum Dis"},{"key":"5316_CR16","doi-asserted-by":"publisher","first-page":"h1389","DOI":"10.1136\/bmj.h1389","volume":"350","author":"N van Herwaarden","year":"2015","unstructured":"van Herwaarden N, van der Maas A, Minten MJM et al (2015) Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 350:h1389","journal-title":"BMJ"},{"key":"5316_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00296-017-3780-8","volume":"37","author":"CS Lau","year":"2017","unstructured":"Lau CS, Gibofsky A, Damjanov N et al (2017) Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatol Int 37:1789\u20131798","journal-title":"Rheumatol Int"},{"key":"5316_CR18","first-page":"152","volume":"35","author":"M Jiang","year":"2017","unstructured":"Jiang M, Ren F, Zheng Y et al (2017) Efficacy and safety of down-titration versus continuation strategies of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis with low disease activity or in remission: a systematic review and meta-analysis. Clin Exp Rheumatol 35:152\u2013160","journal-title":"Clin Exp Rheumatol"},{"key":"5316_CR19","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","volume":"56","author":"CJ Edwards","year":"2017","unstructured":"Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K (2017) Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective. Rheumatology 56:1847\u20131856","journal-title":"Rheumatology"},{"key":"5316_CR20","unstructured":"Komiya T, Minegishi-Takase K, Sakurai N et al (2017) Predictive factors associated with successful down-titration of biologics for rheumatoid arthritis patients in clinical practice [abstract 827]. Arthritis Rheumatol 69(suppl 10)"},{"key":"5316_CR21","doi-asserted-by":"crossref","unstructured":"Dierckx S, Lauwerys BR, Sokolova T et al (2018) Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost effective in daily clinical practice: DATA from the Brussels UCL RA cohort [abstract 625]. Arthritis Rheumatol 70(suppl 10)","DOI":"10.1136\/annrheumdis-2018-eular.6342"},{"key":"5316_CR22","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00296-018-4087-0","volume":"38","author":"L Valor","year":"2018","unstructured":"Valor L, Garrido J, Mart\u00ednez-Estupi\u00f1\u00e1n L et al (2018) Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs. Rheumatol Int 38:1465\u20131470","journal-title":"Rheumatol Int"},{"key":"5316_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-019-1937-4","volume":"21","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P (2019) The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Res Ther 21:164. https:\/\/doi.org\/10.1186\/s13075-019-1937-4","journal-title":"Arthritis Res Ther"},{"key":"5316_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3109\/14397595.2015.1123349","volume":"26","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Nagaoka S, Lee SK et al (2016) Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Mod Rheumatol 26:651\u2013661","journal-title":"Mod Rheumatol"},{"key":"5316_CR25","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"5316_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10067-018-4355-0","volume":"38","author":"A Mart\u00ednez-Feito","year":"2019","unstructured":"Mart\u00ednez-Feito A, Plasencia-Rodr\u00edguez C, Navarro-Comp\u00e1n V et al (2019) The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol 38:949\u2013954","journal-title":"Clin Rheumatol"},{"key":"5316_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/rheumatology\/key244","volume":"58","author":"CH Brahe","year":"2019","unstructured":"Brahe CH, Krabbe S, \u00d8stergaard M et al (2019) Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors. Rheumatology 58:110\u2013119","journal-title":"Rheumatology"},{"key":"5316_CR28","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s10067-016-3413-8","volume":"35","author":"Y El Miedany","year":"2016","unstructured":"El Miedany Y, El Gaafary M, Youssef S et al (2016) Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol 35:2915\u20132923","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05316-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05316-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05316-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T23:25:31Z","timestamp":1629501931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05316-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["5316"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05316-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"23 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The ethics committee of Munster, Germany, had approved the study (registration number: 2018\u2013208-f-S).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Each patient had provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provided consent to publish.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The software application will be available on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}